Alkaline phosphatase for treating an inflammatory disease of the gastro-intestinal tract
AssigneePharmaaware Sepsis B.V.
InventorsRudi Brands, Klaas Poelstra
Life of this patent
Estimating the term…
Abstract
The present invention provides a use for alkaline phosphatase for the manufacture of a medicament for the prevention or reduction of toxic LPS influx through a mucosal lining of a mammalian body cavity. A source of alkaline phosphatase is administered for the prophylaxis or treatment of LPS mediated or exacerbated diseases. The invention also provides compositions comprising a source of alkaline phosphatase for the prevention or reduction of (toxic) LPS influx or passage through mucosal layers.
Claims8
A method for preventing or reducing LPS toxicity at an intestinal mucosa in a subject, comprising administering a composition comprising a source of alkaline phosphatase (AP) that is suitable for preventing or reducing lipopolysaccharide (LPS)-induced toxicity at the intestinal mucosa to a subject suffering from a gastro-intestinal (GI) tract inflammatory disease selected from the group consisting of Crohn's disease, enterocolitis, and ulcerative colitis, wherein the AP is delivered to the GI tract of the subject to treat said GI tract inflammatory disease.
Dependencies are inferred from the claim text.